87 results about "Diabetic animal" patented technology

The invention discloses a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 system and application thereof to construction of swine-derived recombinant cells with insulin receptor substrate gene defects. The invention provides an sgRNA (ribonucleic acid) combination which is composed of sgRNAIRS1-1, sgRNAIRS1-3, sgRNAIRS2-2 and sgRNAIRS2-3. The invention provides a plasmid combination. The plasmid combination is composed of four plasmids, and the four plasmids are respectively subjected to transcription to obtain sgRNAIRS1-1, sgRNAIRS1-3, sgRNAIRS2-2 and sgRNAIRS2-3. Theapplication of the sgRNA combination or the plasmid combination is as follows: preparation of recombinant cells; preparation of a diabetic cell model; preparation of a diabetic animal model. Accordingto the invention, sgRNAIRS1-1 is as shown in SEQ ID NO:8; sgRNAIRS1-3 is as shown in SEQ ID NO:10; sgRNAIRS2-2 is shown as SEQ ID NO:14; and sgRNAIRS2-3 is as shown in SEQ ID NO:15. A solid foundation is laid for the preparation of diabetic pig models, and important application value for the research and development of diabetic medicaments is achieved.

The present invention relates to novel antagonists to a B1-bradykinin (B1-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B1 receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B1-BK receptors in these two models. B1-BK antagonists abolished the vasocontraction induced by B1-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B1-antagonists are useful for treating any condition wherein B1-receptor is expressed, particularly during inflammation, and more particularly wherein B1-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B1-receptor.

The present invention provides an antioxidative composition with high safety, which is capable of lessening oxidative stress due to active oxygen species, free radicals, or the like in vivo, thereby preventing the occurrence or worsening of a disease. It was confirmed that by using a composition containing oxidized coenzyme Q and / or reduced coenzyme Q, the amount of urinary 8-hydroxydeoxyquanosine can be decreased in normal or diabetic animals. Also, in histopathological research of the spleens of diabetic rats, it was confirmed that spleen tissue denaturation caused by oxidative stress can be prevented. It was thus found that oxidative stress in vivo can be lessened. According to the present invention, oxidative stress in vivo can be lessened by using a composition containing coenzyme Q as an active ingredient.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

The invention provides a separation and purification method of a human umbilical cord mesenchymal stem cell exosome and an application of the human umbilical cord mesenchymal stem cell exosome, and belongs to the technical field of medicines. The human umbilical cord mesenchymal stem cell exosome provided by the invention is prepared by cultivating human umbilical cord mesenchymal stem cells via aserum-free medium, collecting supernatant liquid, implementing centrifuging as well as ultra-filtration and concentration, transferring a concentrated solution onto a 30% sucrose-heavy water densitypad and implementing further purification through sucrose density centrifuging, so that the human umbilical cord mesenchymal stem cell exosome is obtained. According to the separation and purificationmethod that the human umbilical cord mesenchymal stem cell exosome is obtained through separation and purification, immunoreactivity is effectively reduced, and a controllable dosage when the human umbilical cord mesenchymal stem cell exosome is used is guaranteed. The human umbilical cord mesenchymal stem cell exosome, by improving a degree of activating an insulin signaling pathway of a type IIdiabetes animal model, can inhibit composition and decomposition of hepatic glycogen, so that glucose metabolism homeostasis can be achieved; and meanwhile, the sensitivity of the type II diabetes animal model to insulin and an insulin secretion function of pancreatic [beta] cells can be improved and a blood glucose concentration can be reduced, so that the application of the human umbilical cordmesenchymal stem cell exosome to the preparation of medicines for treating type II diabetes can be achieved.

The present invention generally relates to implantable devices for producing insulin in diabetic animals. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and / or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and / or rejection by the host.

The invention provides a method for establishing an SD mouse fat and diabetes research model through diet and STZ induction. Through high-fat feed and STZ induction, the attacking characteristics of fat and diabetes of humans are induced, and an animal model for establishing pathogenesis of fat and type-2-diabetes caused by insulin resistance and partial defects of pancreatic beta cells is provided. Mice are divided into a normal control group, a fat group and a diabetes group, and each group has six SD male mice. The high-fat feed is adopted for feeding mice for eight weeks, a pure-fat insulin resistance model is induced, after the mice are fed with the high-fat feed for eight weeks, injection of STZ small doze in batch is conducted, and establishment of the diabetes animal model is induced. The method can better simulate the attacking characteristics of human type-2-diabetes caused by improper diet and enjoinment factors currently, and compared with other modeling, the method has better scientific significance of clinical and fundamental research combination.

The invention provides a method for preparing holothuria nobilis from fresh ginseng, an effect of the holothuria nobilis on diabetes mellitus, and application of the holothuria nobilis in a drug for treating the diabetes mellitus. The holothuria nobilis is characterized by being prepared from the fresh ginseng by steps of repeatedly steaming by high-temperature steam for 2-9 times and drying. A diabetes mellitus animal model proves that the holothuria nobilis has the effects of reducing blood sugar level, improving glucose tolerance, regulating blood fat, protecting and repairing damaged islet after administration treatment of the holothuria nobilis. The substance can be applied to prevention and treatment of the diabetes mellitus.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention discloses a high fat feed and a type II diabetes animal model. The high fat feed comprises the following raw materials: corn, expanded soybean, wheat bran, fish meal, flour, alfalfa powder, lard, cholesterol, white granulated sugar, vitamin premix, and mineral premix. The provided high fat feed can induce rhesus monkeys to generate the symptoms of type II diabetes. The harm caused by drug induction to animals can be avoided. The interference caused by drugs in the development of drugs for treating diabetes can also be eliminated. The dosage in drug induction is hard to control, and the dietary induction effectively solves the abovementioned problem. The generated model has the characteristics of high incidence rate, long maintenance time, and stability, and animals will not die easily. A standard animal model is provided for the researches on type II diabetes.

The present invention generally relates to implantable devices for producing insulin in diabetic animals and to methods of making same. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and / or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and / or rejection by the host.

The invention relates to a mugwort extract, a new application thereof and a preparation process thereof, especially a mugwort extract and a preparation process thereof and application thereof in controlling postmeal gucose. The technical scheme comprises: keeping active ingredients of water or ethanol extract of mugwort leaf or mugwort leaf and mugwort stem, and removing useless dregs; applying the mugwort extract to controlling the postmeal gucose in the field of diabetes mellitus prevention and treatment drugs and health food. The invention has the advantages that resources are rich, economic and easy to obtain; the preparation process is simple, low in cost, short in production period, suitable for industrial production, convenient in application, obvious in effect, low in dosage and convenient to carry, store and use. The extract is applied to treating animal diabetes mellitus model, thereby obviously reducing postmeal gucose, improving insulin resistance and decreasing the typical symptoms of diabetes; thus, the invention has remarkable advantage in reducing and deferring diabetic complications and development thereof. Furthermore, the invention shows that the mugwort preparation has good prevention effect on diabetes and diabetic complications. The invention meets the requirements of modern traditional Chinese medicines for triple effects, triple low aspects and triple convenience aspects.

A method for separating and culturing insulin dry cell from pancreatic tissue and inducing into pancreatic cell is carried out by separating pancreatic cell aggregate, adding it into culture dish with culture medium A for 2-5days, inoculating suspended pancreatic cell aggregate into culture dish with culture medium B, culturing for 6-20days to grow asteriform pancreatic dry cell, sub-culturing to obtain pancreatic dry cell, inoculating it culture dish with culture medium C, culturing for 2-5days, replacing culture medium C with culture medium D, and culturing for 4-15days to obtain the final product.

The invention discloses application of an oleanolic acid and retinoic acid pharmaceutical composition to medicament for treating insulin resistance and diabetes. Intraperitoneal injection of the oleanolic acid and retinoic acid pharmaceutical composition to diabetic animal can significantly lower the blood glucose level; and addition of the oleanolic acid and retinoic acid pharmaceutical composition in culture solution for culturing liver cells can significantly promote transmission of an insulin signal. Therefore, the oleanolic acid and retinoic acid pharmaceutical composition can be applied to medicaments for treating diabetes, insulin resistance and metabolic syndrome closely related to insulin resistance.

The invention discloses a novel compound formed by the chemical coupling of a diphenylethlene compound and derivatives thereof as well as thiazolidine or oxazolidine midbody and a preparation method thereof. The invention also discloses a plurality of pharmaceutical applications of the compounds: reducing blood sugar, serum insulin level and triglycercide level of a diabete II animal model, treating diseases related to the insulin tolerance, such as polycystic ovary syndrome, hyperlipemia, coronary disease and ambient vascular diseases, and also treating inflammations and immunological diseases, especially diseases mediated by cytokines and cyclooxygenase cox, such as THF-Alpha, IL-1, IL-6 and / or COX-2.

The invention relates to application of phloretin in preparation of medicine for preventing and treating diabetes. A spontaneous diabetes animal model kkay mouse for transferring Ay genes is introduced, the influence of phloretin on related indexes such as blood glucose and blood fat of diabetes in the mouse is researched, an antidiabetic effect of the phloretin is proved, and a basis is provided for applying the phloretin to the medicine for preventing and treating diabetes.

The invention belongs to the technical field of strain preparation, and discloses a bifidobacterium animalis and a preparation method thereof. The preservation number of the bifidobacterium animalis is CGMCC No:12944. The bifidobacterium animalis NMC disclosed by the invention is separated from the intestinal tract of a healthy 100-year-old person, the strain has extremely high acid resistance, capable of resisting gastric acid to successfully arrive at the intestinal tract, and an intestinal tract experiment proves that the strain has the probiotic functions of significantly alleviating constipation, improving intestinal flora, alleviating ulcerative colitis, enhancing the pancreatic islet function and fat metabolism of animals with type II diabetes, decreasing the triglyceride and cholesterol level in blood and the like, so the strain is an excellent probiotic strain; and the bifidobacterium animalis can treat constipation, prevent and treat tumors, protect the liver, treat cardiovascular disease, improve lactose digestion and delay senescence.

The invention provides application of resveratrol in medical titanium alloy implants under the condition of diabetes. The application has the advantages that by establishing a medical titanium alloy surface osteogenesis cell culture system, the following key treatment functions of the resveratrol are demonstrated, namely that the cell activity of titanium-bone interface osteogenesis cell in diabetes is improved; the osteogenic differentiation efficiency of the osteogenesis cell is improved; the adhesion state of the osteogenesis cell on the material surface is improved; the capacity of the osteogenesis cell resisting oxidizing stress injury caused by diabetes environment is improved; the pathological apoptosis of the osteogenesis cell is reduced; in addition, the osseointegration effect of the medical titanium alloy implant in a diabetes animal is improved by the resveratrol; the resveratrol can be used as a new drug or titanium alloy implant functional improving composite material ingredient to improve the osseointegration effect of the titanium alloy implant of a diabetes patient.

A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S, 4S)-6-fluoro-2′,5′-dioxospiro [chroman-4,4′-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia / reperfusion to express edema in a retinal visual cell layer or in a macula lutea

The invention provides a composition for constructing an animal model of diabetes mellitus type II and application of the composition to preparing feeds or drugs for constructing the animal model of the diabetes mellitus type II, wherein the composition comprises a conjugated linoleic acid mixture of which the weight percentage is more than 0.1% relative to the composition; and the animal model of the diabetes mellitus type II is prepared by feeding the composition to the mouse. Because the conjugated linoleic acid mixture or a single conjugated linoleic acid monomer is adopted as an inducer and the mouse is adopted as the animal protomodel, compared with a traditional chemical drug or diet induced animal model of the diabetes mellitus type II, the composition provided by the invention has the advantages of low price, convenience and easiness for raw material obtaining; and because the model establishing time is 4-6 weeks, the period is short, the formed model is characterized by hyperglycemia, high insulin level and in-vivo insulin resistance, the composition accords with basic characteristics of the diabetes mellitus type II and is an ideal composition for constructing the animal model of the diabetes mellitus type II.

The invention provides a construction method of a type I diabetes animal model. The method comprises the following steps: selecting C57BL / 6 mice, performing first tail vein injection, continuously performing intraperitoneal injection of a streptozotocin reagent for 5 days, performing ambrosia for 12 hours before injection, and allowing the mice to freely drink water. Two days after the injection procedure is completed, the ambrosia is carried out for 4 hours, and a glucometer is used for measuring blood glucose until the blood glucose value is 10 mmol / L or above. The statistical analysis of the blood glucose measurement result of the type I diabetes animal model shows that the C57BL / 6 mouse type I diabetes model constructed by using the streptozotocin is feasible and can be used for researching the diabetes pathogenesis and the anti-hyperglycemia intervention of medicaments and health-care foods. Compared with the prior art, the C57BL / 6 mouse type I diabetes model constructed by the invention has the advantages of high film forming rate, simple operation, no death of animals and good reproducibility.

A method for dedifferentiating adipose tissue stromal cells (ATSC) is provided. When the ATSC is treated under hypoxia condition and with a 4-(3,4-Dihydroxy-phenyl)-derivative (DHP-derivative), expression of stemness genes, cellular growth-related genes and cellular mobility-related genes increase, and expression of histone and DNA methylation-related genes decrease so that cell proliferation increases and pluripotency for differentiating into adipocytes, osteocytes, myocytes, beta cells and cartilage cells is acquired. When the dedifferentiated ATSC is implanted into animal model with spinal cord injury and diabetic animal model, effects of nerve regeneration and increased blood surge level are confirmed. As a result, the method for dedifferentiating the ATSC can be effectively used in the stem cell research, tissue regeneration and development of cytotherapeutic medicines.

The invention relates to the technical field of probiotics, in particular to a composition of lactobacillus paracasei LC-37 and application of the composition in reducing blood sugar. According to the invention, the lactobacillus paracasei LC-37 has new functions of promoting the secretion of the glucagon-like peptide 1, reducing blood sugar and relieving the symptoms of diabetes mellitus; the lactobacillus paracasei LC-37 is further compounded with the dietary fibers, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is remarkably improved, and the composition of the lactobacillus paracasei LC-37 and the dietary fibers can remarkably reduce the blood glucose of diabetic animals, relieve oral glucose tolerance damage, reduce the insulin resistance index and regulate blood fat. The traditional Chinese medicine composition can improve intestinal mucosal barrier and pancreatic tissue damage, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.

The invention relates to the technical field of an application of a lactoflavin ester derivative and a composition containing the component for preparing a medicine for treating diabetes mellitus and complication thereof. After an accessory material is added into the lactoflavin ester derivative, the mixture can be made into a dosage form of capsules, tablets, granules, injection, and the like. The lactoflavin ester derivative has the functions of promoting the consumption of preadipocyte glucose, activating peroxisome paraphyte activated receptor gamma, reducing the blood sugar of a diabetes mellitus animal model, increasing sensibility on insulin, improving the pancreatic island function and a pancreatic island form and lightening the pathologic change of a diabetic nerve, a diabetic retina, a diabetic kidney and diabetic feet.

The invention provides a method for establishing an SD-rat diabetes model through combination of high-fat diet with induction of STZ. An animal model with type-2 diabetes pathogenesis which is causedby insulin resistance and partial defects of islet B cells is established through clinical characteristics of simulation of human obesity and diabetes by using high-fat feed and STZ induction. SPG-grade SD male rats are divided randomly into normal control groups of 10 rats per group and diabetic groups of 20 rats per group. The rats of 4 weeks old are fed with high-fat diet so that induction of the insulin-resistant model is achieved, and low-dose tail-vein injection of STZ is performed 12 weeks after the rats are fed with the high-fat diet so that establishment of the animal model of diabetes can be induced. Through the method, the clinical characteristics of human type-2 diabetes which is caused by insulin resistance and hyposecretion of insulin can be simulated better, and compared with other modeling methods, the method has more scientific significance of combination of clinic and basic research.

The invention belongs to the technical field of animal models of diabetes mellitus, and particularly relates to a modeling method for an animal model of type 2 diabetes mellitus. The method comprisesthe step that 20-100 lumens and 8-10 hours of illumination is applied during nighttime animal sleep for induction, wherein the induction time is 2-6 month. The method provided by the invention fills the blank of modeling of the animal model of the type 2 diabetes mellitus by a natural induction method, shortens the modeling time of the animal model, and has fewer side effects; and the problems such as too serious obesity and too high mortality of individuals do not easily occur, and feeding costs are greatly reduced.

The invention discloses a method for inducing type 2 diabetes animal model through low-temperature and dietary rhythm regulation and control. By combining the regulation and control of a low-temperature environment with the change of the dietary rhythm of a feeding feed or independently through the change of a dietary rhythm of the feeding feed, or through only the change of the dietary rhythm ofthe feeding feed, the animal is induced to form type 2 diabetes animal model with weight gain, hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance as main markers. Experimental research results show that SD rats can be induced to form main markers of type 2 diabetes such as weight gain, hyperlipidemia, hyperglycemia, hyperinsulinemia and insulin resistance by low-temperature environment and night time-limited diet, the diversity of intestinal microorganisms can be remarkably reduced, the morbidity mode is close to that of human type 2 diabetes, and the constructed diabetes animal model can be used for studying a morbidity mechanism of type 2 diabetes, searching related targets of early diagnosis, and researching and developing treatment drugs and prevention and treatmentmethods.

The invention discloses a method for constructing a diabetes mellitus animal model, which comprises the following steps: an alloxan reagent is injected in the abdominal cavity of a selected Kunming white mouse; then the white mouse is fed in a cage independently; water and food are fed to the white mouse quantitatively; after the white mouse is forbidden to eat food for 12 hours, blood is taken from the tail of the white mouse; a blood sugar meter is used for detecting a blood sugar value, and when the blood sugar value is larger than or equal to 10.0 mmol / L, the steps are ended. Proved by a statistical analysis of a blood sugar measuring result of the diabetes mellitus animal model, the method for constructing a white mouse diabetes mellitus model by utilizing the alloxan is feasible, and the model can be used as a research model of the pathogenesis and the drug mechanism of diabetes mellitus. Moreover, compared with the prior art, the constructed while mouse diabetes mellitus model has the advantages of simple model constructing method, high model forming rate, low cost, short period, good reproducibility, and the like.

The invention provides an active component of peanut shells, which is obtained by leaching peanut shells with ethanol, suction filtration, concentration, separation with macroporous adsorption resin, and fraction collection. In anti-obesity and diabetes in vivo experiments, the present invention has confirmed that the active components of peanut coat can regulate adiponectin and leptin signaling pathways to reduce body weight and blood sugar through animal models of diabetes, and can significantly reduce experimental obesity mice and 2 The food intake, body weight and blood sugar level of type 2 diabetes model mice can significantly improve the clinical symptoms of obesity and diabetes. It can be used in the preparation of food, health food and medicine for preventing and treating obesity and diabetes.